Trial NCT03714815

View at ClinicalTrials.gov 
Org. Study IDs: AC-055G203
Secondary IDs: 2018-001603-37

Last trial update was posted on 2023-09-22

MeSH Interventions

Macitentan

MeSH Conditions

Heart Failure Vascular Diseases

Other Conditions

Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Stopping Reasons

the absence of a positive trend in all efficacy parameters indicates that macitentan 10 mg does not have a beneficial effect in patients with HFpEF and PVD.

Limitations And Caveats

Limited number of efficacy parameters were assessed in an exploratory manner. Study was stopped prematurely as main double-blind study did not meet the primary efficacy outcome measure.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID